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76 Poster Session-Iand 606 7.8%, respectively. The 1 and 5yr overall survival (OS) for
pts with non-malignant disease was 826 6.6%. The 5yr OS in chil-
dren with PGF was 45.5 6 15%. In conclusion, RI-AlloSCT is safe
and well tolerated in children; RI-AlloSCT is associated with signif-
icantly lower NRM and high sustained donor chimerism. However,
chemo-naı¨ve children receiving UCB have a higher incidence of
PGF and need alternative conditioning.205
UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION IS AN
EFFECTIVE THERAPY FOR WISKOTT-ALDRICH SYNDROME
Sun, J.M., Driscoll, T., Prasad, V.K., Parikh, S., Szabolcs, P.,
Kurtzberg, J., Martin, P.L. Duke University, Durham, NC
Background: Patients with severe Wiskott-Aldrich Syndrome
(WAS) characterized by absent WAS protein rarely survive beyond
20 years. Infections, hemorrhage and malignancy are leading causes
of death. Allogeneic bone marrow transplant corrects immune func-
tion and thrombocytopenia and prolongs survival. However, many
children lack an appropriate donor. This study investigated the fea-
sibility of unrelated umbilical cord blood (UCB) as an alternative
source of stem cells in WAS patients lacking HLA-matched bone
marrow donors.
Methods: Fifteen children with severe WAS received 16 unre-
lated UCB transplants at Duke University from 2/1998 to 12/
2007. All patients received myeloablative chemotherapy (busulfan,
cyclophosphamide, ATG 6 fludarabine). Patients were evaluated
for engraftment, graft versus host disease (GvHD), survival and ef-
fects on the natural history of disease.
Results:UCB units matched at$4/6 HLAmarkers had a median
precryopreservation total nucleated cell dose of 7.95  107 cells/kg.
All patients engrafted with donor cells (one after a second UCB
transplant). Median times to neutrophil (ANC. 500/uL) and plate-
let (.50k/L) engraftment were 21 (range 10–38) and 67 (range 46–
139) days, respectively. One patient has mixed chimerism, all others
maintained complete donor chimerism post-transplant. Four
patients experienced grade II-IV acute GvHD and 11/12 evaluable
patients experienced limited (n 5 10) or extensive (n 5 1) chronic
GvHD. Six patients died post-transplant of gut GvHD with adeno-
virus, extensive chronicGvHDwith EBV lymphoproliferative disor-
der, multisystem organ failure, and three of infection alone
(Klebsiella, parainfluenza, adenovirus). Nine patients are surviving
with a median follow-up of 89 months (range 9–127), an overall sur-
vival of 60%. Survivors have normal platelets, minimal eczema or
other medical issues. All school-age children are attending school.
Conclusions:Unrelated UCB is a readily available source of stem
cells for patients with WAS. UCB transplant corrects the immuno-
deficiency and thrombocytopenia caused byWAS and favorably im-
pacts the natural history of disease. An increased incidence of limited
chronic skin GvHD was noted compared to that reported in UCB
transplant recipients with other diagnoses, perhaps related to pro-
inflammatory state of the skin due to pre-transplantWAS-associated
eczema. UCB transplantation should be considered for all patients
with severe WAS lacking a matched adult or related bone marrow
donor.206
SIGNIFICANCE OF HLA-B ANTIGEN MATCHING IN EVENT FREE SURVIVAL
(EFS) IN PEDIATRIC UMBILICAL CORD BLOOD TRANSPLANTATION
(CBT): EXPERIENCE FROM 124 SINGLE CBT AT CHILDREN’S MEMORIAL
HOSPITAL (CMH), CHICAGO
Merchant, M., Chaudhury, S., Duerst, R., Jacobsohn, D., Tse, W.T.,
Schneiderman, J., Kletzel, M. Children’s Memorial Hospital, Northwest-
ern University Feinberg School of Medicine, Chicago, IL
Objective: To evaluate the significance of HLA antigen match-
ing/ mismatching in CBT outcomes in the pediatric patient.
Method: Between 1995- 2007, 124 single CBTwere performed at
CMH for treatment of malignancy (85) or non-malignancy (39). Dis-
eases included ALL (39), AML (29), MDS (7), NBL (2), other malig-
nancies (8), SCID (11), THAL (3), WISK (3), Osteopetrosis (4), AA
(2), Fanconi’s (2), other non-malignancies (14). Status at transplant
for malignancies: CR1 (42%), CR2 (44%), CR $3 (7%) and PR(7%). Cord blood units were processed as described by Rubenstein
et al. Recipients were 55 female, 69 male, median age at transplant
3.7 yrs (0.56 – 20.8), weight 20 kg (3- 73). 113 pts (91%) received
myelo-ablative therapy of fTBI 6 VP, Cy, TT (84), Bu, Cy 6 VP
(21) or TT, Cy 6 FLUD (8) 11 pts (9%) received non-ablative reg-
imen of VP, Cy, or FLUD 6 Bu, Cy. GVHD prophylaxis was CSA
1MTX 1 ATG . Prior to 2000, HLA matching for class was done
by serologic typing. Later, high level molecular typing was done for
HLA-DRB1. Degree of HLA matching was 6/6 (13), 5/6 (29), 4/6
(74), 3/6 (7). 5/6 HLA group: single mismatch on HLA-A (13),
HLA-B (10), HLA-DRB1 (6). 4/6 HLA group: 2 mismatches,
HLA-B (9) and DRB1 (1); other 64 pts had 1 mismatch on different
antigens: A (43), B (51), DRB1 (34). 3/6HLA group: 4 pts had 1 mis-
match on each HLA antigen 3 patients had 2 mismatches on HLA-B
1 another mismatch. 30 patients (24%) died of TRM. 17 of 85 pts
(20%) relapsed. 39% developed acute GVHD grade II/IV and
6.5% chronic GVHD. OS is 56% and EFS is 48% with median fol-
low up of 763 days.
Results: Matching/mismatching at HLA-A, or HLA-DRB1
showed no statistical significance in TRM or EFS. Degree of
HLA-B matching showed statistical significance in TRM and EFS
(p-value 0.001). EFS, HLA-A: 1 match 56.5%; 2 matches 54.9%.
EFS, HLA-B: 0 match 18.3%; 1 match 48.6%; 2 matches 72.3%.
EFS, HLA-DRB1: 1 match 64%; 2 matches 51.1%. TRM, HLA-
B: 11% (2 matches, n 5 46), 31% (1 match, n5 65); 42% (0 match,
n5 12). However, in analyzing the 4/6 HLA group alone, TRM for
HLA-B antigen was 7% (2 matches), 25% (1 match) and 22% (0
match). In this group, the rate of relapse for pts with malignancy
was 18% (2 matches), 5.7% (1 match) and 83.3% (0 match).
Conclusion: In pediatric CBT, TRM and Relapse increase with
increasing HLA-B mismatch; and Event Free Survivals improve
when HLA-B antigens are matched.207
TARGETING TO AN OPTIMAL AUC OF INTRAVENOUS BUSULFAN PRE-
VENTS GRAFT FAILURE IN TRANSPLANTATION IN CHILDREN WITH
NON-MALIGNANT DISEASES
Bartelink, I.H.1, Bredius, R.G.M.2, Bierings, M.1, Egeler, M.2,
Lankester, A.C.2, Egberts, T.C.G.1, Zwaveling, J.2, Boelens, J.J.1
1UMCU, Utrecht, Netherlands; 2LUMC, Leiden, Netherlands
Background: Busulfan combined with therapeutic drug monitor-
ing guided dosing is associated with higher event free survival (EFS)
rates due to less graft-failure/relapses and lower toxicity in haemato-
logical stem cell transplantation (HSCT). In an earlier study, our
group showed an optimal AUC between 74–82 mg*h/L with respect
to event free survival (EFS) in a group of children withmalignant and
non-malignant indications. Non-malignant diseases, especially in-
born error of metabolism (IEM) are known to be associated with
high graft-failure rates. Therefore we analysed the influence of the
‘‘lower’’ limit of the (previously found) optimum of Busulfan AUC
on graft-failure.
Methods: All children, transplanted between 2001–2008 in 2
Dutch pediatric transplant centers, receiving intravenous busulfan
as part of a myeloablative regimen for non-malignant indications,
were included. The association between an AUC below or above
the lower limit of the optimum (74mg*h/L) and the main endpoints
graft-failure and EFS and the toxicity endpoints treatment related
mortality (TRM), acute-Graft-versus-Host Disease grade 2–4
(aGvHD) and Veno-occlusive Disease (VOD), were tested using
uni- and multivariable Cox regression analysis.
Results: 70 patients were included (28 patients with IEM, 36 with
immune defiencies (including Hemophagocytic Lympho-Histiocy-
tosis) and 5 patients with bone marrow failures). Indications were
equally distributed over the 2 groups. The median follow up time
was 2.5 years (range 1–370 weeks). The AUC in the lower group
ranged from 35.0–73.7 mg*h/L while those in the higher group
ranged from 74.5 to 98.7 mg*h/L. EFS-rate in the \74mg*h/L
group was negatively influenced by Graft-failure (18%, vs 0% in pa-
tients receiving.74mg*h/L,HR5 0.2, P5 0.016). EFSwas 72% vs
82% in the \74 mg*h/L and .74 mg*h/L group, respectively.
aGvHD grade 2–4 did occur more frequently in patients receiving
a high exposure of busulfan (5% vs 19%: p 5 0.2). No difference
in TRM (P5 0.8) and VOD (P5 0.9) occurrence was noted as well.
Poster Session-I 77Conclusion: Dose targeting of busulfan to an AUC above 74
mg*h/L prevents graft failures in patients with non-malignant dis-
eases and is not associated with higher toxicity. Outcomes might
be optimized further by targeting a narrower AUC window: a mini-
mum AUC to ensure engraftment, and a maximum to minimize the
busulfan-associated toxicity.208
GROWTH AND CGVHD IN PEDIATRIC PATIENTS UNDERGOING REDUCED
INTENSITY CONDITIONING FOR HEMATOPOIETIC STEM CELL TRANS-
PLANT AS COMPARED TO TRADITIONAL MYELOABLATIVE CONDITION-
ING
Danner-Koptik, K.E.1, Koss, M.2, Duerst, R.1,3, Kletzel, M.1,3,
Dilley, K.J.1,3 1Children’s Memorial Hospital, Chicago, IL; 2Harvard
University, Cambridge, MA; 3Northwestern University, Chicago, IL
Background: Reduced intensity conditioning (RI) regimens are
used as an alternative to traditional myeloablative conditioning
(MA) for allogeneic hematopoietic stem cell transplant (HSCT) in
children. The main rationale is to allow tumor kill while decreasing
the degree of acute toxicity due to conditioning regimen, which
could potentially also decrease the occurrence of late effects.
Objective: To examine growth parameters and prevalence of
chronic graft versus host disease (CGvHD) at specific timepoints
in pediatric survivors of RI HSCT as compared to matched controls
who received MA.
Design/Methods: Medical record review of all patients who re-
ceived a RI HSCT from 2000 to 5/2007 at a single institution, ex-
cluding patients who ever received .1 HSCT, survived\100 days
post RI HSCT or had a primary diagnosis that would affect growth
directly. Remaining patients were matched to MA recipients by age
at HSCT andmalignancy yes/no. It was not always possible tomatch
for HSC source. Any occurence of CGvHD (McNemar test) and
growth data (paired T-test) were analyzed at 1y and latest follow-
up available.
Results:MAmatches were found for 34/44 patients who received
a single RI HSCT. Mean age at first transplant was 9.45y for RI and
9.84y forMA (p5 0.15). 20/34 pairs (59%) were same gender. 24/34
pairs (71%) were matched for related/unrelated, and 17/34 pairs
(50%) agreed for both matched/unmatched and related/unrelated.
21/34 (62%) were matched for HSC source, all mismatches were
RI peripheral blood HSCs with MA bone marrow (n 5 12) or
cord blood (n 5 1). The length of follow-up to latest visit differed
between RI patients at mean 966 (range 462–2512) days and MA at
2025 (range 525–4538) days (p5 0.006). No differences seen in Ta-
ble 1 were significant, although 1 year height Z scores approached
significance with p 5 0.051.
Growth parameters and prevalence of CGvHD at specific
timepoints
RI MA RI MA1 year (n531) Latest F/U (n531)Extensive CGvHD 3/31 (10%) 6/31 (19%) 2/31 (6%) 1/31 (3%)
1 year (n515)1 Latest F/U (n510)1Height Z score –0.78 –0.14 –0.86 –0.47
BMI Z score 0.13 0.98 1.01 1.311Full growth parameters, especially height, were not available at all visits.
Conclusions: At specific follow-up timepoints, there was no dif-
ference in CGvHD prevalence or in growth parameters between
age- and diagnosis-matched RI and MA HSCT recipients. This
study did not allow survival curve analysis of CGvHD, as occurrence
was only assessed at specific timepoints. Height Z scores were less
than zero at all timepoints, indicating that growth is affected both
by RI andMA regimens. Longer follow-upwill be necessary to ascer-
tain if growth effects are different over time between RI and MA re-
cipients, and this study by design will also assess differences in late
effects such as endocrine or other organ system dysfunction.209
REDUCED INTENSITY CONDITIONING (RIC) IS ASSOCIATED WITH A SIG-
NIFICANT DECREASE IN DAY 1100 NON-RELAPSE MORTALITY (NRM),
GRADE II-IV AGVHD AND OVERALL SURVIVAL (OS) IN PEDIATRIC RECIP-
IENTS FOLLOWING CORD BLOOD TRANSPLANTATION (CBT)
Cairo, M.S.1,2,3, Jin, Z.4, van de Ven, C.1, Tallamy, B.1, Schonfeld, T.1,
Moore, V.1, Harrison, L.1, Morris, E.1, Bhatia, M.1, George, D.1,
Garvin, J.H.1, Bradley, M.B.1, Schwartz, J.3, Baxter-Lowe, L.A.5,
Satwani, P.1 1Morgan Stanley Children’s Hospital New York Presbyte-
rian, Columbia University, New York, NY; 2Columbia University, New
York, NY; 3Columbia University, New York, NY; 4Columbia University,
New York, NY; 5University of California San Francisco, San Francisco,
CA
We and others have demonstrated that myeloablative condition-
ing (MAC) and CBT results in a high engraftment rate and lower
severe AGVHD rate but a 20–40% incidence of Day 1100 NRM
(Cairo et al BBMT, 2008). RIC and AlloSCT in adults have been
associated with a decrease in acute toxicity and NRM (Satwani/
Cairo et al BBMT, 2005). Our group recently demonstrated the
safety and sustained high donor chimerism following RIC and
UCBT in pediatric recipients (Bradley/Cairo et al BMT, 2007).
In this study we investigated the risk factors associated with Day
1100 NRM, Grade II-IV AGVHD and OS in 101 consecutive
CBT pediatric recipients. Probability of Day 1100 NRM and OS
were calculated by Kaplan Meier estimates. Continuous variables
are summarized as mean 6 SD and categorical variables as %.
Risk factors for Grade II-IV AGVHD and Day1100 NRMwas as-
sessed by logistic regression and and OS was assessed by Cox pro-
portional hazards; variables \0.2 in univariate were included in
multivariate analyses. Risk factors: RIC vs MAC, average vs poor
risk, malignant/non, HLA 4/6 vs $4/6, CMV donor/recipient,
CD34\2.3 vs $2.3  105 CD34/kg, TNC 3, $3\5, $5  107
TNC/kg, Grade II-IV AGVHD, chronic GVHD. 101 pts, age
7.6 6 6.5 yrs; M/F 60/40%; MAC/RIC 55/45%; average/poor
risk 74/26%; CMV -/- 26%; HLA 4/6 52%; malignant/non 66/
34%. Median time to ANC and platelet recovery was similar be-
tween RIC and MAC CBT (24 vs 24) and (59 vs 64) d, respectively.
Day 180 and 365 chimerism was also similar (84 vs 89%) and (89 vs
92%), respectively. However, the probability of Grade II-IV
AGVHD was significantly less following RIC 20% (CI95 8.3%–
31.7%) vs 42.9% (CI95 29.9%–55.8%%) (p\ 0.015). Multivariate
analysis demonstrated the following independent risk factors in
Grade II-IV AGVHD: High CD34 hazard ratio (HR): 3.1,
p\0.02; HLA 4/6 HR: 4.2, p\0.007 and MAC HR: 4.1,
p\0.005. Day 1100 NRM was significantly less following RIC
2.3% (CI95 0–6.7%) vs. 26.1% (CI95 14.3%–37.8%), p\0.002.
The only significant factor in Day 1100 NRM was MAC HR:
27.2, p\0.005. Lastly, 3yr OS was significantly improved following
RIC 56% (CI95 37–70) vs MAC 28% (CI95 16–40) and the follow-
ing risk factors: Low vs High CD34 HR: 1.0 vs 0.38, p\0.004;
and MAC HR: 2.9, p\0.001 were associated with a significant
improvement in OS. In summary, RIC was the single most impor-
tant risk factor associated with a significant reduction in Grade II-
IV AGVHD, Day 100 NRM and OS in pediatric recipients
following CBT.210
DIFFERENCES IN MONITORING AND TREATMENT OF CRITICALLY ILL
CHILDREN DURING OR AFTER HEMATOPOETIC STEM CELL TRANSPLANT
McArthur, J.A.1, Christensen, M.A.1, Tamburro, R.F.2, Jouvet, P.3,
Pettersen, G.3 1Medical College of Wisconsin, Milwaukee, WI; 2Pennsyl-
vania State University, Hershey, PA; 3St. Justine Hospital, Montreal,
QC, Canada
Background: Pediatric hematopoetic stem cell transplant
(HSCT) recipients requiring critical care services historically have
poor outcomes. There appears to be a wide range of clinical ap-
proaches to this patient population. Clinical trials utilizing evi-
denced-based protocols are needed to improve outcomes. A better
understanding of the variations in care of these patients is needed
to design future trials. The Pediatric Acute Lung Injury and Sepsis
Investigators (PALISI) Network surveyed the most active United
States pediatricHSCTprograms regarding the care provided to crit-
ically ill patients.
